Phase 3 study · Dianthus Therapeutics · NCT07647510
Dianthus's phase 3 claseprubart study for myasthenia gravis
About 195 adults are planned, each assigned by chance to claseprubart every 2 weeks, claseprubart every 4 weeks or a placebo. After an infusion on day 1, shots under the skin follow every 2 weeks for 17 weeks, and neither participants nor study doctors know which.
Get an email when it adds US sites
It is enrolling now. We send an email only when it adds a US site, so you hear if one opens nearer to you. Your email is used for nothing else.
Free email alert
Hear when Dianthus's phase 3 claseprubart study opens near you
One email when it starts enrolling or lists a new site, with the sites and how to reach the study team. Nothing else.
Opening and new sites for this study only. Stop anytime. We never share your email. Privacy policy
Check the main requirements privately
These questions restate the study's public listing in plain words. Your answers stay on this device and are never sent. You can print a one-page summary to go over with your neurologist.
1. Are you an adult between 18 and 80 years old?
2. Do you weigh between 40kg and 130kg, about 88 to 287 pounds?
3. Has a blood test shown that you have acetylcholine receptor (AChR) antibodies?
Your neurologist's office can tell you whether your AChR antibody test was positive.4. Have you had an abnormal nerve and muscle test, a positive anticholinesterase test, or improvement on a medicine such as pyridostigmine?
The listing needs only 1 of these 3, along with a positive AChR antibody test. Nerve and muscle tests include repetitive nerve stimulation and single-fiber EMG, and pyridostigmine is also sold as Mestinon.5. Is your latest MG-ADL score, the 8-question daily activities score, 6 or higher?
The study team checks this score itself when deciding who can join the study. Your neurologist's office may have your latest MG-ADL score in your records.6. Have you had surgery on your thymus gland, or a thymus biopsy, in the past year?
7. Have you, a parent, a sibling or a child ever been diagnosed with lupus (SLE)?
The study team also checks for these, which are easier to go over with your neurologist:
- Generalized myasthenia gravis rated MGFA class II to IVa, and a muscle strength exam (QMG) score of 10 or more
- Records of vaccines against encapsulated bacteria, following local requirements and vaccine availability
- A known complement deficiency, or any past N. meningitidis (meningococcal) infection
- A thymoma that is known or untreated, any thymus cancer, or an active cancer in the past 5 years, with a few listed exceptions such as some skin cancers
- Rituximab or another B-cell medicine such as inebilizumab in the past 6 months, or IVIg or plasma exchange in the past 4 weeks
- HIV, hepatitis B or hepatitis C infection, earlier claseprubart (DNTH103), or another study drug in the past 90 days
Sites and contact
US sites from the public ClinicalTrials.gov record, refreshed every hour. Only the study team decides who can join.
- Clinical Study SitePasadena, California · Recruiting
- Cinical Study SiteBoca Raton, Florida · Recruiting
- Cinical Study SiteFayetteville, North Carolina · Not yet recruiting
- Cinical Study SiteHouston, Texas · Recruiting
Every site's own contact and the full eligibility list are on the official ClinicalTrials.gov listing for NCT07647510.
Questions people ask about Dianthus's phase 3 claseprubart study
Is Dianthus's phase 3 claseprubart study enrolling now?
ClinicalTrials.gov lists it as recruiting, as of its last update there on 2026-10-30. Only the study team can confirm whether a particular site is still taking people.
Where are the US sites for Dianthus's phase 3 claseprubart study?
The listing names 4 US sites, in California, Florida, North Carolina, Texas. The full list is in the sites section of this page.
Who can join Dianthus's phase 3 claseprubart study?
About 195 adults are planned, each assigned by chance to claseprubart every 2 weeks, claseprubart every 4 weeks or a placebo. The main listed requirements are in the pre-check on this page, starting with: adults 18 to 80 years old. Only the study team decides who can join.
How do I contact the Dianthus's phase 3 claseprubart study team?
The listing names this contact: Dianthus Clinical Contact Center, 929-999-4055, clinicaltrials@dianthustx.com. Each site may also list its own contact on ClinicalTrials.gov.
Is Trial Friend part of this study?
No. Trial Friend is independent of this study and its sponsor, Dianthus Therapeutics. This page restates the public listing in plain words, and nothing here is medical advice; talk with your neurologist about whether a study is right for you.
From the public ClinicalTrials.gov record NCT07647510, last updated there 2026-10-30. Questions checked against the listing on November 10, 2026. Trial Friend is independent of this study and its sponsor, and is not a medical provider. Nothing here is medical advice; talk with your neurologist about whether a study is right for you.